Keep Updated October 2017

Washington Summary October 2017

Health Care On Sept. 26, Senate Majority Leader Mitch McConnell (R-KY) indicated that the Senate would not vote on the most recent attempt to amend the Affordable Care Act (ACA).  Sens. Lamar Alexander (R-TN) and Patty Murray (D-WA) may seek […]

PKD Foundation |

Tolvaptan and lixivaptan: what’s the difference?

In response to the news about lixivaptan’s orphan drug designation, there have been questions from the PKD community about the difference between the investigational drug and another potential ADPKD treatment, tolvaptan. Tolvaptan and lixivaptan are vasopressin V2 receptor antagonists, meaning […]

PKD Foundation |

Lixivaptan granted orphan drug status for ADPKD

An investigational drug being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD) has received orphan drug designation by the U.S. Food and Drug Administration (FDA). Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which may delay […]

PKD Foundation |